Abstract
Shear wave elastography (SWE) is a noninvasive ultrasound-based marker of hepatic fibrosis not requiring a special device. Successful direct-acting anti-HCV therapy was associated with hepatic fibrosis regression assessed by transient elastography (FibroScan). Data on the utility of SWE in these patients and how early fibrosis can regress after treatment are still lacking. To assess liver fibrosis by SWE before and after direct-acting antiviral treatment of chronic hepatitis C (CHC), we enrolled 165 CHC genotype 4 Egyptian patients treated with different Sofosbuvir-based regimens. Patients’ laboratory characteristics, fibrosis biomarkers, namely Fibrosis-4 (FIB-4) index and AST/platelet ratio index (APRI) and liver stiffness measurements (LSM) by SWE were evaluated at baseline, end of treatment (EOT at week 12), week 24 and week 36. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels as well as FIB-4 and APRI indices decreased significantly at EOT, week 24 and week 36 in comparison to baseline (P value < 0.001). Although platelet counts did not significantly differ between baseline and EOT, they increased significantly from EOT to week 24 and week 36 with a P value < 0.001. The mean LSM showed improvement at EOT (7.01 ± 3.59 kpa), week 24 (6.18 ± 3.39 kpa) and week 36 (5.74 ± 3.21 kpa) in comparison to baseline (8.49 ± 0.83 kpa) (P value < 0.001). There is early liver fibrosis regression at EOT and throughout the time after successful treatment with direct-acting antiviral agents (DAAs). SWE is a feasible, easily applicable noninvasive relatively inexpensive assessment method of liver fibrosis.
Similar content being viewed by others
References
Lombardi A, Mondelli MU. Hepatitis C: Is eradication possible? Liver Int. 2019;39:416–26.
Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med. 2017;9:17–25.
Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
Refaat B, Ashshi AM, El-Shemi AG, AlZanbagi A. Effects of chronic hepatitis C genotype 1 and 4 on serum activins and follistatin in treatment naïve patients and their correlations with interleukin-6, tumour necrosis factor-α, viral load and liver damage. Clin Exp Med. 2015;15:293–302.
Latif HA, Assal HS, Mahmoud M, Rasheed WI. Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin Exp Med. 2011;11:123–9.
Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56:1171–80.
Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013–21.
Omran D, Yosry A, Darweesh SK, et al. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients. Clin Exp Med. 2018;18:45–50.
Kohla MAS, Abbasy M, Abozeid M, et al. Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study. Eur J Gastroenterol Hepatol. 2017;29:951–5.
Ragazzo TG, Paranagua-Vezozzo D, Lima FR, et al. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao Paulo). 2017;72:516–25.
Bucsics T, Grasl B, Ferlitsch A, et al. Point shear wave elastography for non-invasive assessment of liver fibrosis in patients with viral hepatitis. Ultrasound Med Biol. 2018;44:2578–86.
Abozeid M, Alsebaey A, Abdelsameea E, et al. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis. 2018;75:109–14.
Das D, Pandya M. Recent advancement of direct-acting antiviral agents (DAAs) in hepatitis C therapy. Mini Rev Med Chem. 2018;18:584–96.
Jiang HJ, Wang XX, Luo BF, et al. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients. Clin Exp Med. 2019;19:299–308.
Elsharkawy A, Alem SA, Fouad R, et al. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol. 2017;32:1624–30.
Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. Hepat Med. 2017;9:45–53.
Lu M, Li J, Zhang T, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol. 2016;14(1044–55):e3.
El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017;24:262–7.
Ferraioli G, Filice C, Castera L, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 3: liver. Ultrasound Med Biol. 2015;41:1161–79.
Mohamed R, Amin M, Omar H, Rabea MY, Abd Elazeem MA. Quantitative assessment of liver fibrosis in chronic viral hepatitis C patients using shear wave elastography with elastography point quantification feature. Egypt J Radiol Nucl Med. 2017;48:31–42.
Suda T, Okawa O, Masaoka R, et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol. 2017;9:64–8.
Tada T, Kumada T, Toyoda H, et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017;32:1982–8.
Korda D, Lenard ZM, Gerlei Z, et al. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence. Eur J Gastroenterol Hepatol. 2018;30:27–32.
Van der Meer AJ, Maan R, Veldt BJ, et al. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31:1168–76.
Acknowledgements
We deeply thank the viral hepatitis treatment clinic team at the National liver institute, Menoufia University, Egypt for their help & support.
Funding
None.
Author information
Authors and Affiliations
Contributions
MASK, MA, MA: Design of the study. AEF, MA, MA, ME: Data Collection. ME, AEF: Procedures (LSM). MASK, MA, SW: Data analysis. MASK, MA, AEF: Manuscript writing. SW, MASK, MA: Revision, editing & rewriting.
Corresponding author
Ethics declarations
Conflict of interest
All the authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the institutional review board of the National Liver Institute, Menoufia University and was conducted in compliance with the Declaration of Helsinki.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kohla, M.A.S., Fayoumi, A.E., Akl, M. et al. Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy. Clin Exp Med 20, 143–148 (2020). https://doi.org/10.1007/s10238-019-00597-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-019-00597-0